CTMX logo

CytomX Therapeutics (CTMX) EBITDA

Annual EBITDA

$26.76 M
+$31.07 M+721.10%

December 31, 2024

Summary

Performance

1-Year Change

+721.1%

3-Year Change

+123.61%

5-Year Change

+119.27%

15-Year Change

+163.8%

CTMX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

82.82%
CTMX annual EBITDA is higher than 82.82% of companies in Healthcare sector

High & Low

All-time High

$26.76 M
CTMX annual EBITDA is currently at an all-time high

3-Year Low

-$113.34 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
CTMX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
CTMX next annual earnings announcement has not yet been scheduled

OtherCTMXprofitabilitymetrics:

Annual Revenue

$138.10 M
CTMX annual revenue is $138.10 million

Annual Net Income

$31.87 M
CTMX annual net profit is $31.87 million

Annual EBIT

$25.00 M
CTMX annual earnings before interest & taxes is $25.00 million

Annual EPS

$0.38
CTMX annual earnings per share is $0.38

Quarterly EBITDA

$18.09 M
+$13.55 M+298.50%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+401.58%

5-Year Change

+401.58%

CTMX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

85.24%
CTMX quarterly EBITDA is higher than 85.24% of companies in Healthcare sector

High & Low

All-time High

$18.09 M
CTMX quarterly EBITDA is currently at an all-time high

3-Year Low

-$57.89 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
CTMX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 8, 2025
CTMX next earnings announcement is scheduled for May 8, 2025

OtherCTMXprofitabilitymetrics:

Quarterly Revenue

$38.09 M
CTMX quarterly revenue is $38.09 million

Quarterly Net Income

$18.88 M
CTMX quarterly net profit is $18.88 million

Quarterly EBIT

$17.68 M
CTMX quarterly earnings before interest & taxes is $17.68 million

Quarterly EPS

$0.23
CTMX quarterly earnings per share is $0.23

TTM EBITDA

$26.76 M
+$18.21 M+212.98%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+304.47%

5-Year Change

+304.47%

CTMX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

81.57%
CTMX TTM EBITDA is higher than 81.57% of companies in Healthcare sector

High & Low

All-time High

$26.76 M
CTMX TTM EBITDA is currently at an all-time high

3-Year Low

-$147.88 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
CTMX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 8, 2025
CTMX next earnings announcement is scheduled for May 8, 2025

OtherCTMXprofitabilitymetrics:

TTM Revenue

$138.10 M
CTMX TTM revenue is $138.10 million

TTM Net Income

$31.87 M
CTMX TTM net profit is $31.87 million

TTM EBIT

$25.00 M
CTMX TTM earnings before interest & taxes is $25.00 million

TTM EPS

$0.39
CTMX TTM earnings per share is $0.39

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$26.76 M
CTMX annual EBITDA is $26.76 million

Annual Net Income

$31.87 M
CTMX annual net profit is $31.87 million

Annual Interest Expense

-
CTMX annual interest expense value is unknown

Annual Income Tax

$224.00 K
CTMX annual income tax is $224.00 thousand

Annual D&A

$1.77 M
CTMX annual depreciation & amortization is $1.77 million

CTMX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+721.1%0.0%0.0%
3 y3 years+123.6%+401.6%+304.5%
5 y5 years+119.3%+401.6%+304.5%

CTMX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+123.6%at high+131.3%at high+118.1%
5 y5-yearat high+119.3%at high+126.9%at high+118.1%
alltimeall timeat high+119.3%at high+126.9%at high+118.1%

CytomX Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$26.76 M(-721.1%)
$18.09 M(+298.5%)
$26.76 M(+213.0%)
Sep 2024
-
$4.54 M(-156.8%)
$8.55 M(+12.2%)
Jun 2024
-
-$7.99 M(-165.9%)
$7.62 M(-40.8%)
Mar 2024
-
$12.12 M(<-9900.0%)
$12.87 M(-398.7%)
Dec 2023
-$4.31 M(-95.6%)
-$120.00 K(-103.3%)
-$4.31 M(-67.1%)
Sep 2023
-
$3.61 M(-231.7%)
-$13.09 M(-71.4%)
Jun 2023
-
-$2.74 M(-45.9%)
-$45.78 M(-36.8%)
Mar 2023
-
-$5.06 M(-43.2%)
-$72.49 M(-26.7%)
Dec 2022
-$98.89 M(-12.7%)
-$8.90 M(-69.4%)
-$98.89 M(-33.1%)
Sep 2022
-
-$29.09 M(-1.2%)
-$147.88 M(+5.1%)
Jun 2022
-
-$29.44 M(-6.4%)
-$140.76 M(+8.4%)
Mar 2022
-
-$31.46 M(-45.7%)
-$129.84 M(+14.6%)
Dec 2021
-$113.34 M(+45.4%)
-$57.89 M(+163.6%)
-$113.34 M(+11.7%)
Sep 2021
-
-$21.96 M(+18.5%)
-$101.49 M(+8.2%)
Jun 2021
-
-$18.53 M(+23.9%)
-$93.78 M(+3.3%)
Mar 2021
-
-$14.95 M(-67.5%)
-$90.76 M(+16.4%)
Dec 2020
-$77.97 M(-43.9%)
-$46.05 M(+223.3%)
-$77.97 M(-21.5%)
Sep 2020
-
-$14.24 M(-8.2%)
-$99.27 M(-9.8%)
Jun 2020
-
-$15.52 M(+619.7%)
-$110.07 M(-12.0%)
Mar 2020
-
-$2.16 M(-96.8%)
-$125.12 M(-9.9%)
Dec 2019
-$138.88 M
-$67.36 M(+169.0%)
-$138.88 M(+43.4%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$25.04 M(-18.1%)
-$96.83 M(+2.5%)
Jun 2019
-
-$30.57 M(+92.1%)
-$94.46 M(+23.2%)
Mar 2019
-
-$15.91 M(-37.1%)
-$76.68 M(+0.9%)
Dec 2018
-$75.99 M(+81.1%)
-$25.31 M(+11.7%)
-$75.99 M(+55.5%)
Sep 2018
-
-$22.67 M(+77.2%)
-$48.86 M(+33.0%)
Jun 2018
-
-$12.79 M(-15.9%)
-$36.74 M(-24.9%)
Mar 2018
-
-$15.22 M(-935.7%)
-$48.95 M(+16.7%)
Dec 2017
-$41.95 M(-26.6%)
$1.82 M(-117.3%)
-$41.95 M(-26.2%)
Sep 2017
-
-$10.55 M(-57.8%)
-$56.84 M(-6.5%)
Jun 2017
-
-$25.00 M(+204.2%)
-$60.77 M(+22.6%)
Mar 2017
-
-$8.22 M(-37.1%)
-$49.58 M(-12.5%)
Dec 2016
-$57.19 M(+76.4%)
-$13.07 M(-9.7%)
-$56.68 M(+4.2%)
Sep 2016
-
-$14.47 M(+4.8%)
-$54.38 M(+7.2%)
Jun 2016
-
-$13.81 M(-9.8%)
-$50.75 M(+20.8%)
Mar 2016
-
-$15.32 M(+42.1%)
-$42.03 M(+29.6%)
Dec 2015
-$32.43 M(+11.7%)
-$10.78 M(-0.6%)
-$32.43 M(+24.3%)
Sep 2015
-
-$10.84 M(+113.0%)
-$26.09 M(+40.8%)
Jun 2015
-
-$5.09 M(-10.9%)
-$18.53 M(+37.9%)
Mar 2015
-
-$5.71 M(+28.5%)
-$13.44 M(+74.0%)
Dec 2014
-$29.03 M(+104.1%)
-$4.45 M(+35.7%)
-$7.72 M(+135.7%)
Sep 2014
-
-$3.28 M
-$3.28 M
Dec 2013
-$14.22 M
-
-

FAQ

  • What is CytomX Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics annual EBITDA year-on-year change?
  • What is CytomX Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics quarterly EBITDA year-on-year change?
  • What is CytomX Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics TTM EBITDA year-on-year change?

What is CytomX Therapeutics annual EBITDA?

The current annual EBITDA of CTMX is $26.76 M

What is the all time high annual EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high annual EBITDA is $26.76 M

What is CytomX Therapeutics annual EBITDA year-on-year change?

Over the past year, CTMX annual EBITDA has changed by +$31.07 M (+721.10%)

What is CytomX Therapeutics quarterly EBITDA?

The current quarterly EBITDA of CTMX is $18.09 M

What is the all time high quarterly EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high quarterly EBITDA is $18.09 M

What is CytomX Therapeutics quarterly EBITDA year-on-year change?

Over the past year, CTMX quarterly EBITDA has changed by $0.00 (0.00%)

What is CytomX Therapeutics TTM EBITDA?

The current TTM EBITDA of CTMX is $26.76 M

What is the all time high TTM EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high TTM EBITDA is $26.76 M

What is CytomX Therapeutics TTM EBITDA year-on-year change?

Over the past year, CTMX TTM EBITDA has changed by $0.00 (0.00%)